Effects of ultra-low dose hormone therapy on biochemical bone turnover markers in postmenopausal women: A randomized, placebo-controlled, double-blind trial.
Lúcia Helena Simões da Costa PaivaMaria Celeste O WenderRogerio B MachadoLuciano M PompeiEliana A NahasJorge Nahas-NetoSonia Y Del DebbioMariangela BadalottiAchilles M CruzPublished in: Post reproductive health (2022)
Women receiving E2 0.5/NETA 0.1 experienced reductions in bone resorption and formation markers, an expected effect during the anti-resorptive therapy, suggesting a protective bone effect with the Ultra-LD HT.
Keyphrases
- bone mineral density
- postmenopausal women
- placebo controlled
- double blind
- low dose
- body composition
- phase iii
- study protocol
- clinical trial
- phase ii
- bone loss
- high resolution
- randomized controlled trial
- soft tissue
- stem cells
- high dose
- pregnant women
- adipose tissue
- phase ii study
- open label
- radiation therapy
- pregnancy outcomes
- mass spectrometry
- cell therapy